Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of CBP-1008 in FRα-positive platinum-resistant ovarian, primary peritoneal, and fallopian tube cancers
CTR20222941Phase 2Active
- Sponsor
- Toshidun Pharma
- Start
- Mar 2023
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ricorfotide vedotin in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by Toshidun Pharma. Started Mar 2023; status: active.
02
Drugs
ricorfotide vedotin
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on CTR20222941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222941.